Related Experiment Video

Updated: Aug 24, 2026

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
08:05

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening

Published on: July 18, 2012

Fungal biofilms and drug resistance

Mary Ann Jabra-Rizk1, William A Falkler, Timothy F Meiller

  • 1Department of Diagnostic Sciences and Pathology, Dental School, University of Maryland, Baltimore, Maryland 21201, USA. mar002@dental.umaryland.edu

Emerging Infectious Diseases
|April 14, 2004
PubMed

Insights

Emerging Candida species cause difficult-to-treat nosocomial infections, often on medical devices. New antifungal drugs like echinocandins show promise against resistant Candida biofilms.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Candida species, including Candida dubliniensis, are increasingly causing hospital-acquired infections.
  • Candida biofilms on medical devices, like catheters, are a significant clinical challenge.
  • Biofilm-associated fungal infections are often resistant to standard antifungal treatments due to mechanisms like drug efflux pumps.

Purpose of the Study:

  • To highlight the challenges posed by drug-resistant Candida biofilms.
  • To review novel antifungal agents effective against these resistant biofilms.
  • To discuss the implications for treating invasive fungal infections.

Main Methods:

  • Literature review of antifungal resistance in Candida biofilms.
  • Analysis of emerging antifungal agents and their efficacy.
  • Discussion of clinical implications for biofilm-associated infections.

Main Results:

  • Candida biofilms exhibit broad resistance to conventional antifungals.
  • Novel antifungal classes, including lipid formulations of amphoterins and echinocandins, show activity against resistant biofilms.
  • These newer agents represent a breakthrough for treating systemic mycoses.

Conclusions:

  • Antifungal drug resistance in Candida biofilms necessitates the development of targeted therapies.
  • Lipid formulations of amphoterins and echinocandins offer effective treatment options for biofilm-associated candidiasis.
  • Advances in treating fungal implant infections are expected with drugs targeting biofilms.

More Related Videos

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Growth of Mycobacterium tuberculosis Biofilms09:03

Growth of Mycobacterium tuberculosis Biofilms

Published on: February 15, 2012

Related Concept Videos

Biofilms01:29

Biofilms

Biofilms are complex communities of microorganisms encased in a self-produced extracellular polysaccharide matrix attached to surfaces. These microbial consortia can include single or multiple species, providing enhanced survival benefits by forming organized, multilayered structures.The formation of biofilms occurs through four key stages: attachment, colonization, development, and dispersal.During attachment, free-swimming planktonic cells adhere to a surface, often facilitated by...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...